Equity Insider News
Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, April 2,
2025 /PRNewswire/ --
Equity Insider News Commentary –
Artificial Intelligence (AI) is quickly becoming a major force in
healthcare, as use of AI applications in medical fields is growing
rapidly. Researchers at Dartmouth recently conducted the first
clinical trial of a therapy chatbot powered by generative AI
(genAI), and found that it resulted in significant improvements in
participants' symptoms. Cleveland Clinic and UAE-based
G42 recently started collaborating on the advancement of
even more AI in healthcare adoption, signalling an international
push in this revolution. Because of this, the market is paying even
more attention to developers in tech that are adding tools to the
mix, with recent updates coming from Avant Technologies,
Inc. (OTCQB: AVAI), Apple Inc. (NASDAQ: AAPL),
Amazon.com, Inc. (NASDAQ: AMZN), Spectral AI, Inc.
(NASDAQ: MDAI), and GE HealthCare Technologies Inc.
(NASDAQ: GEHC).
The article continued: Billionaire Bill
Gates recently predicted that he thinks AI will make
medical advice free and commonplace, changing healthcare at a rapid
pace along the way. Private company Layer Health just raised
a fresh $21 million to take on
Healthcare AI's scalability challenges, with investment from
Define Ventures, Flare Capital Partners, GV
and MultiCare Capital Partners.
Avant Technologies Partner, Ainnova, to Sponsor and Present
at 2025 Healthcare Innovation Summit in Mexico City
Avant Technologies, Inc. (OTCQB: AVAI), an emerging
leader in AI-driven healthcare innovation, continues to build
momentum in the AI-driven healthcare sector through its joint
venture with Ainnova Tech, developers of the Vision AI
platform. Today, the two companies announced that Ainnova
will sponsor and present at the 2025 Mexico Healthcare Innovation
Summit—an international event focused on digital transformation and
diagnostics.
Ainnova's CEO, Vinicio
Vargas, will present on preventative healthcare powered by
artificial intelligence, highlighting the practical impact of its
Vision AI platform on early disease detection, which the company
recently began designing the clinical trial protocols for
ahead of a pre-submission meeting with the US Food and Drug
Administration (FDA).
Vargas's appearance at the event reinforces a consistent
strategy for Avant and Ainnova: increasing visibility
across key international markets ahead of major regulatory
milestones to come.
It also follows Ainnova's recent strategic
alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform
has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared
across the Americas.
As previously mentiond, Ainnova is being guided by global
CRO Fortrea ahead of the important pre-submission meeting
with the FDA. The goal is to seek 510(k) clearance for
Vision AI in detecting diabetic retinopathy, a gateway to broader
use across multiple chronic disease categories.
Avant and Ainnova jointly control Ai-nova
Acquisition Corp. (AAC), which holds global licensing rights to
the technology portfolio, including proprietary retinal cameras and
algorithms validated on more than 2.3 million clinical data
points.
Between FDA progress, high-profile alliances, and a
growing international presence, Avant Technologies continues
to carve out a niche in the convergence of AI, diagnostics, and
preventative care. Investors looking for small-cap exposure to the
healthcare AI revolution may want to keep AVAI on the radar
as these developments unfold.
CONTINUED... Read this and more news for Avant
Technologies at:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-
need-to-know/
Apple Inc. (NASDAQ: AAPL) is reportedly working on
an AI-driven health coach, under the codename Project Mulberry, as
a revamped version of its Health app. For a while now, CEO
Tim Cook has been promising that
Apple's long-term plans include a big push into more
health-related technologies.
According to Bloomberg's Mark
Gurman, Apple could launch this as early as next
year alongside a future iOS update. The service would give users
tips on diet and exercise, using data from the Health app and
Apple devices like the Apple Watch.
It's still unclear whether this tool will act more like a real
medical assistant or just a health and wellness coach. Gurman
describes it as an "AI doctor service," and the report says it's
being trained using real data from doctors and medical
professionals. The service might be called Health Plus and could
become a major part of Apple's growing services
business.
Amazon.com, Inc. (NASDAQ: AMZN) is pushing deeper into
genAI itself, including testing health assistants with a chatbot
tool focused on health and wellness, called Health AI, which can
answer health and wellness questions, "provide common care options
for health care needs," and suggest products.
Already, Amazon's shopping chatbot, Rufus, can suggest
products like ice packs and ibuprofen. Where Health AI goes further
will be in providing users with medical guidance and care tips,
such as how to deal with flu or cold symptoms. Health AI also
steers users to Amazon's online pharmacy, along with clinical
services offered by One Medical, the primary care
provider it acquired for roughly $3.9
billion in 2022.
Spectral AI, Inc. (NASDAQ: MDAI) recently
announced strong results from its Burn Validation Study,
showing that its DeepView® System outperformed burn physicians in
identifying non-healing tissue.
"We believe these are excellent results and we are thrilled with
the analysis of our DeepView System in our Burn Validation Study,"
said Dr J. Michael DiMaio, M.D. "The
DeepView System exceeded our expectations in terms of predictive
performance. Following the FDA's review, if authorized by
the agency, our hope is that this tool will provide an objective
and immediate prediction of non-healing burn tissue to expedite
patient care and reduce system costs across the board. We look
forward to bringing this predictive diagnostic tool to the United States marketplace as soon as
possible."
The study, one of the largest of its kind in the U.S.,
demonstrated DeepView's superior accuracy using AI and
multispectral imaging to assess burn wounds on day one. The company
plans to submit the data to the FDA by mid-2025, aiming for
De Novo Clearance and rapid commercialization.
GE HealthCare Technologies Inc. (NASDAQ:
GEHC) recently unveiled its new Revolution™ Vibe CT system,
featuring advanced AI-powered cardiac imaging that delivers fast,
accurate scans—even in complex cases like atrial fibrillation or
heavy coronary calcification. The system's Unlimited One-Beat
Cardiac imaging and AI-driven workflow aim to improve diagnostic
speed, patient comfort, and operational efficiency across
healthcare facilities.
"Expanding access to CCTA is crucial for managing the rising
prevalence of CVD, ensuring timely and accurate diagnoses for a
larger patient population," shares Jean-Luc
Procaccini, President and CEO, Molecular Imaging and
Computed Tomography, GE HealthCare. "Our introduction of
Revolution Vibe underscores our commitment to this mission. The
system is designed to encourage the broader adoption of and access
to cardiac imaging, combining advanced technology with AI-powered
solutions to deliver fast, accurate diagnoses and a more
comfortable patient experience. It is designed to empower
healthcare providers to offer the highest quality care, even in the
most challenging cases."
With FDA-recommended CCTA adoption on the rise and
cardiac disease still the leading global cause of death, Revolution
Vibe is designed to expand access to life-saving imaging and reduce
reliance on invasive procedures.
Source:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-
need-to-know/
CONTACT:
Equity
Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
Equity Insider is a wholly-owned subsidiary of Market IQ Media
Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies
Inc. advertising and digital media from the company directly. There
may be 3rd parties who may have shares Avant Technologies Inc., and
may liquidate their shares which could have a negative effect on
the price of the stock. This compensation constitutes a conflict of
interest as to our ability to remain objective in our communication
regarding the profiled company. Because of this conflict,
individuals are strongly encouraged to not use this publication as
the basis for any investment decision. The owner/operator of MIQ
own shares of Avant Technologies Inc. which were purchased in the
open market. MIQ reserves the right to buy and sell, and will buy
and sell shares of Avant Technologies Inc. at any time thereafter
without any further notice. We also expect further compensation as
an ongoing digital media effort to increase visibility for the
company, no further notice will be given, but let this disclaimer
serve as notice that all material disseminated by MIQ has been
approved by the above mentioned company; this is a paid
advertisement, and we own shares of the mentioned company that we
will sell, and we also reserve the right to buy shares of the
company in the open market, or through other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between any predictions and actual results.
Always consult a licensed investment professional before making any
investment decision. Be extremely careful, investing in securities
carries a high degree of risk; you may likely lose some or all of
the investment.
Logo -
https://mma.prnewswire.com/media/2644233/5249022/Equity_Insider_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fda-watch-the-quiet-gold-rush-in-ai-powered-medical-devices-302418679.html
SOURCE Equity Insider
